Supercharged t cells take on Hard-to-Treat cancers

NCT ID NCT07614048

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infused back after a short course of chemotherapy. The goal is to control the disease in patients who have run out of standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
engineered T cells (TCR-T cells) targeting mutant KRAS
What this could lead to
If successful, this could offer a new treatment option for patients with advanced pancreatic or colorectal cancers that have not responded to standard therapies.
What could go wrong
This is an early-stage expanded access program, not a large controlled trial. The treatment may not shrink tumors or improve survival, and there are risks from chemotherapy and cell infusion, including severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPENDICEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.